Clinical Trial

Contrast-enhanced Mammography in Women With a Personal History of Breast Cancer and Dense Breast Tissue: Benefit?

Study acronym: CEM
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
This study aims to assess the effectiveness of Contrast-Enhanced Mammography (CEM)as an alternative to traditional ultrasound for breast cancer screening in women with dense breasts and a personal history of breast cancer. CEM combines standard mammography with a contrast agent to better detect tumors, particularly in women with dense tissue where traditional mammograms may miss signs of cancer. The study will compare CEM with ultrasound and MRI to determine its accuracy in detecting cancer, reduce wait times for screening, and provide a more affordable option than MRI. Women who participate will have their screening done in one visit, improving convenience and access. The study will track cancer detection rates, biopsy results, and patient satisfaction over two years to evaluate the benefits of CEM for early breast cancer detection.
Trial Details
NCT Number NCT06993246
Lead Sponsor Jean Seely
Collaborators: Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma
Conditions Breast Cancer
Enrollment 50 participants
Start Date 2025-09-15
Primary Completion 2026-09-30 (estimated)
Study Completion 2028-09-30 (estimated)
Updated on ClinicalTrials.gov 2025-05-28